Share a Resource
Submit material for the education materials pages. Material will be reviewed by the Communications Committee before posting.
Clin Imm Sōsh - November 2014
Pointing you in the right direction
Welcome to the second issue of Clin Imm Sōsh, the e-newsletter from CIS! We'd like to keep you up to date on CIS's projects and committees, as well as letting you know what's new on the website and social media. As always, we value your input, so if you there are topics you'd like to see more (or less!) of in the newsletter, or you have any other comments, please drop us a line at email@example.com
In memory: Dr. John Fahey
We are saddened to let you know that CIS co-founder Dr. John Fahey passed away on August 19, 2014.
2015 Annual Meeting: Immune Deficiency and Dysregulation North American Conference
The CIS 2015 Annual Meeting is being held April 9 – 12, 2015 at the Hilton Americas in Houston, Texas. Registration will be opening soon, and abstract submission is already open.
In recent years, the Annual Meeting has specifically focused on PIDD every other year. However, the leadership of CIS recognizes that every year there should be a focus on PIDD. We are excited to let you know that beginning in 2015, the CIS Annual Meeting will be renamed, and called the "Immune Deficiency and Dysregulation North American Conference" every year. We hope you're able to join us in Houston!
Coming Soon: CME for the Journal of Clinical Immunology
We are happy to announce that the Journal of Clinical Immunology (JoCI) will be publishing invited review articles written by internationally known experts in the field of primary immunodeficiency diseases (PID). These articles will offer continuing medical education (CME) credits for our readership, provided by the Clinical Immunology Society (CIS), the primary society that sponsors the JoCI. Unlike most reviews published in other journals, these reviews will focus on..
What’s New in Immunotherapeutics - Zoulfia Allakhverdi, PhD
FDA recognizes personalized CAR-T cell therapy CTL019 as “breakthrough therapy”
This update covers investigational chimeric antigen receptor T (CAR-T) cell therapy CTL019 for treatment of adult and pediatric relapsed/refractory acute lymphoblastic leukemia (ALL). On July 2014, FDA granted “Breakthrough Therapy” status to this investigational therapy, which underscored it as the most developmentally advanced CAR-T cell therapy and could possibly speed its arrival to the market. This designation given to Novartis and the Perelman School of Medicine of the University of Pennsylvania on CTL019 includes all of the fast track program features...
2015 Membership renewal
Membership renewal for the 2015 year is coming soon. You will be receiving dues notices directly, first by email and then in the regular mail. This year, we're asking you to update your member profile by letting us know if you see adult and/or pediatric patients, or if you don't see patients. In addition, to better serve our members' needs, we are asking that you let us know your primary specialty.
WEBbook Update coming soon
The Communications Committee is hard at work updating the WEBbook of Biologics. We expect these updates to be completed in December of this year.
2014 Summer School in Primary Immunodeficiency
The Summer School in Primary Immunodeficiency Diseases took place at the Shore Club South Beach in Miami, Florida. This was the 13th meeting sponsored by the Clinical Immunology Society on Primary Immunodeficiency Diseases and proved to be another astounding success.
Submit your articles to JoCI
The Journal of Clinical Immunology is the official journal of CIS. It's a great journal, but we need your help to make it even better. The CIS Council requests that CIS members submit their work to JoCI to make our official journal the strongest it can be. Our impact factor of 2.654 is rising, and we need your participation to improve it further!
Save the Date!